Dr. Rae is a translational neuroscientist known for her extensive expertise on cannabis. She received both her BS in psychology and PhD in neuroscience from Washington State University. Adie completed her postdoctoral training at the University of Sydney (Australia), Columbia University (NY), and Washington University in St. Louis (MO). Currently, she is an Assistant Scientist at Legacy Research Institute, and adjunct faculty at Washington State University. As a Principle Investigator, Dr. Rae is funded by NIDA to characterize the role of the CB1 receptor in opioid tolerance during pain (DA041467). Her human and preclinical research is focused on pain management, addiction, and harm reduction. Dr. Rae’s peer-reviewed publications are indexed in PubMed under the surname Wilson-Poe. Adie is passionate about evidence-based policy and healthcare. She was a member of the healthcare subcommittee for Oregon’s Measure 109, and played a supportive role in its passage. Similar service initiatives include advisory roles with New Approach (supporting Missouri’s legalization of medical cannabis), and Oregon Measure 110. She also serves as an advisor to the Ethical Data Alliance, a non-profit aimed at leveraging blockchain technology to enhance data transparency while preserving privacy. Dr. Rae also takes part in psilocybin round-table discussions with Congressman Earl Blumenauer, in an effort to foster Federal support for the Oregon Psilocybin Services (OPS) program. Thanks to her lengthy service on the Oregon Cannabis Commission, Adie has close ties with Oregon Health Authority, which oversees the OPS. Her research goals include prospective studies and clinical trials examining the efficacy of psilocybin-assisted therapy for chronic pain.